Lithium- and Valproate-Induced Alterations in Circadian Locomotor Behavior in Drosophila

Department of Psychiatry, Washington University in St. Louis, San Luis, Missouri, United States
Neuropsychopharmacology (Impact Factor: 7.05). 01/2006; 30(12):2216-24. DOI: 10.1038/sj.npp.1300764
Source: PubMed


Lithium and valproate are commonly used mood stabilizers, but their action pathways are not clearly understood. They also suffer from multiple toxic effects that limit their utility. Elucidating their action mechanisms could lead to newer agents and better understanding of the etiopathogenesis of bipolar disorder. We have expanded the study of signaling mechanisms of lithium and valproate by using Drosophila circadian locomotor activity as a robust behavioral assay that is amenable to genetic manipulations. We demonstrate that lithium affects the circadian system of Drosophila similarly to what has been reported in the mammalian studies. We show that lithium and valproate share effects on the circadian locomotor activity of Drosophila: they lengthen the period of circadian rhythms and increase arrhythmicity. Valproate exerts these effects in a weaker fashion than does lithium. We also tested the circadian alterations in multiple mutant lines of Drosophila bearing defects in the GSK-3beta gene and other clock genes in response to lithium administration. We show that lithium partially rescues the shortening of circadian period when the GSK-3beta gene is overexpressed only in specific circadian pacemaker neurons, thus implicating GSK-3beta as a component in lithium's effect on the circadian oscillator. Moreover, lithium also lengthens the period in GSK-3beta heterozygous mutants and doubletime long mutants. These results establish a basis for using Drosophila genetics to investigate more fully lithium and valproate action mechanisms.

Download full-text


Available from: Mehmet E. Dokucu, Feb 03, 2015
1 Follower
17 Reads
  • Source
    • "These lithium concentrations were initially chosen based on the paper by Dokucu et al. (2005)—they showed that lithium concentrations ranging from 10 to 100 mM lithium in the fly food translates to roughly 0.05–0.4 mM in the fly tissue (Dokucu et al., 2005), so well below the toxic levels in patients and mice (Wood et al., 1986; Schou, 2001; Can et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The greatest risk factor for Alzheimer's disease (AD) is age, and changes in the ageing nervous system are likely contributors to AD pathology. Amyloid beta (Aβ) accumulation, which occurs as a result of the amyloidogenic processing of amyloid precursor protein (APP), is thought to initiate the pathogenesis of AD, eventually leading to neuronal cell death. Previously, we developed an adult-onset Drosophila model of AD. Mutant Aβ42 accumulation led to increased mortality and neuronal dysfunction in the adult flies. Furthermore, we showed that lithium reduced Aβ42 protein, but not mRNA, and was able to rescue Aβ42-induced toxicity. In the current study, we investigated the mechanism/s by which lithium modulates Aβ42 protein levels and Aβ42 induced toxicity in the fly model. We found that lithium caused a reduction in protein synthesis in Drosophila and hence the level of Aβ42. At both the low and high doses tested, lithium rescued the locomotory defects induced by Aβ42, but it rescued lifespan only at lower doses, suggesting that long-term, high-dose lithium treatment may have induced toxicity. Lithium also down-regulated translation in the fission yeast Schizosaccharomyces pombe associated with increased chronological lifespan. Our data highlight a role for lithium and reduced protein synthesis as potential therapeutic targets for AD pathogenesis.
    Frontiers in Aging Neuroscience 07/2014; 6:190. DOI:10.3389/fnagi.2014.00190 · 4.00 Impact Factor
    • "Data on prescribed psychotropic treatments were recorded for BD cases (none of the HC was being prescribed these medications). This was considered relevant as it is known for example that lithium and valproate lengthen the circadian period [7] [37] and reduce melatonin light sensitivity [10] [11]. Similarly, benzodiazepines and antipsychotics are known to have sedative effects and could act as confounders in this study. "
    Médecine du Sommeil 03/2014; 11(1):33. DOI:10.1016/j.msom.2014.01.078
  • Source
    • "This did not have an effect on overall melatonin secretion or the dim-light melatonin onset time [87]. A study evaluating the circadian effects of valproate on Drosophilia found that the drug lengthened the period of the circadian rhythm and promoted rhythmicity [88]. Real-time PCR analysis on mice and human fibroblasts has shown that the valproate can advance or delay the rhythmic expression of the circadian gene Period2::Luciferace depending on the time of administration [89]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Approximately one-third of patients with epilepsy continue to have seizures despite antiepileptic therapy. Many seizures occur in diurnal, sleep/wake, circadian, or even monthly patterns. The relationship between biomarkers and state changes is still being investigated, but early results suggest that some of these patterns may be related to endogenous circadian patterns whereas others may be related to wakefulness and sleep or both. Chronotherapy, the application of treatment at times of greatest seizure susceptibility, is a technique that may optimize seizure control in selected patients. It may be used in the form of differential dosing, as preparations designed to deliver sustained or pulsatile drug delivery or in the form of 'zeitgebers' that shift endogenous rhythms. Early trials in epilepsy suggest that chronopharmacology may provide improved seizure control compared with conventional treatment in some patients. The present article reviews chronopharmacology in the treatment of epilepsy as well as future treatment avenues.
    Current Neurology and Neuroscience Reports 04/2013; 13(4):339. DOI:10.1007/s11910-013-0339-2 · 3.06 Impact Factor
Show more